Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.44 HKD | +2.95% |
|
-5.45% | -63.40% |
06-05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
06-05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Bearish | Bearish | Bearish |
Resistance | 3.540 | 4.070 | 5.300 |
Spread/Res. | -31.36% | -40.29% | -54.15% |
Spread/Supp. | +49.08% | +49.08% | +84.09% |
Support | 1.630 | 1.630 | 1.320 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- 9966 Stock
- Charts Alphamab Oncology